2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T695,To describe disease activity and treatments received during the postpartum period, breastfeeding rates and their possible impact on rheumatoid arthritis (RA) and spondyloarthritis (SpA) activity. This ancillary study from the French multicentre prospective cohort (GR2-NCT02450396) included pregnant women with RA and SpA with at least one postpartum visit from October 2014 to October 2022. Disease activity, flares, treatments and breastfeeding rates were described. Factors associated with the occurrence of a flare were evaluated by survival analysis. Disease activity was compared according to breastfeeding duration (never, <6 months and ≥6 months). Ninety-four RA and 124 SpA patients were studied. In RA patients, the proportion of patients presenting with at least one flare was significantly higher during the first 6 months postpartum compared with pregnancy (62.0% vs 43.5%; p=0.02). For SpA patients, there was no difference in disease activity at 6 months postpartum compared with pregnancy (40.7% vs 40.7%; p=0.999). Disease activity in postpartum was similar between the different breastfeeding status in both diseases. 13/91 (14.3%) RA patients and 29/123 (23.6%) SpA patients continued a biologic Disease-Modifying Antirheumatic Drug (bDMARD) during the whole pregnancy and the postpartum. 78/91 RA and 94/123 SpA patients delivered without any DMARDs, and among them, 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum. RA patients were more likely to flare during early postpartum, while SpA patients remained stable. bDMARD continuation during pregnancy was more frequent in SpA patients, and half of the patients restarted bDMARD during postpartum.31:T9b8, Objective To describe disease activity and treatments received during the postpartum period, breastfeeding rates and their possible impact on rheumatoid arthritis (RA) and spondyloarthritis (SpA) activity. Method This ancillary study from the French multicentre prospective cohort (GR2- NCT02450396 ) included pregnant women with RA and SpA with at least one postpartum visit from October 2014 to October 2022. Disease activity, flares, treatments and breastfeeding rates were described. Factors associated with the occurrence of a flare were evaluated by survival analysis. Disease activity was compared according to breastfeeding duration (never, <6 months and ≥6 months). Results Ninety-four RA and 124 SpA patients were studied. In RA patients, the proportion of patients presenting with at least one flare was significantly higher during the first 6 months postpartum compared with pregnancy (62.0% vs 43.5%; p=0.02). For SpA patients, there was no difference in disease activity at 6 months postpartum compared with pregnancy (40.7% vs 40.7%; p=0.999). Disease activity in postpartum was similar between the different breastfeeding status in both diseases. 13/91 (14.3%) RA patients and 29/123 (23.6%) SpA patients continued a biologic Disease-Modifying Antirheumatic Drug (bDMARD) during the whole pregnancy and the postpartum. 78/91 RA and 94/123 SpA patients delivered without any DMARDs, and among them, 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum. Conclusion RA patients were more likely to flare during early postpartum, while SpA patients remained stable. bDMARD continuation during pregnancy was more frequent in SpA patients, and half of the patients restarted bDMARD during postpartum. 32:T6e7,We examine coverage of self-administered disease-modifying antirheumatic drugs (DMARDs) in Medicare Part D. Using 2022-2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin-6 (IL-6) inhibitors, and JAK inhibitors. We measured (1) coverage of individual DMARDs and (2) the generosity of coverage between classes (the share of plans covering at least one drug in each class) and within classes (the share of covered drugs within each class). We included 26,915 plan-year observations, representing 217.6 million enrolled beneficiaries from 2022 to 2026. In the five-year period, coverage was relatively complete (>94%) for etanercept and adalimumab (TNF inhibitors) and upadacitinib (JAK inhibitor). However, coverage was lower for golimumab and certolizumab (TNF inhibitors), abatacept (the sole T cell costimulatory modulator), sarilumab (IL-6 inhibitor), and baricitinib (JAK inhibitor). Moreover, only 10.4% and 37.6% of stand-alone and Medicare Advantage (MA) Part D plans, respectively, covered all mechanisms of action, mostly due to low coverage of abatacept. In 2026, only 0.3% and 21.2% of stand-alone and MA Part D plans, respectively, covered abatacept. On the other hand, coverage increased for IL-6 inhibitors, likely due to the availability of biosimilar drugs for tocilizumab in 2024. The growing exclusions of self-administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted.33:T949, Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL‐6) inhibitors, and JAK inhibitors. We measured (1) coverage of individual DMARDs and (2) the generosity of coverage between classes (the share of plans covering at least one drug in each class) and within classes (the share of covered drugs within each class). Results We included 26,915 plan‐year observations, representing 217.6 million enrolled beneficiaries from 2022 to 2026. In the five‐year period, coverage was relatively complete (>94%) for etanercept and adalimumab (TNF inhibitors) and upadacitinib (JAK inhibitor). However, coverage was lower for golimumab and certolizumab (TNF inhibitors), abatacept (the sole T cell costimulatory modulator), sarilumab (IL‐6 inhibitor), and baricitinib (JAK inhibitor). Moreover, only 10.4% and 37.6% of stand‐alone and Medicare Advantage (MA) Part D plans, respectively, covered all mechanisms of action, mostly due to low coverage of abatacept. In 2026, only 0.3% and 21.2% of stand‐alone and MA Part D plans, respectively, covered abatacept. On the other hand, coverage increased for IL‐6 inhibitors, likely due to the availability of biosimilar drugs for tocilizumab in 2024. Conclusion The growing exclusions of self‐administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"golimumab: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on golimumab (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/golimumab\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"golimumab\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/golimumab\"}]}}"}}]],["$","$L2f",null,{"title":"golimumab: Research & Clinical Takeaways","description":"Explore research on golimumab (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0490","pmid":"42708647","title":"The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0490","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:16.284Z","updated_at":"2026-09-12T06:20:16.284Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Rapamune","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Simponi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"condition","value":"Cutaneous Sarcoidosis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"sirolimus","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"thalidomide","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"Antimycobacterial Combination Therapy","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"Immunomodulatory Agent","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"mTOR Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"TNF-alpha Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"sample_size","value":"n=156","value_numeric":156},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"Only 6 RCTs with 156 participants were pooled; the meta-analysis is substantially underpowered and results should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"Publication bias could not be formally assessed due to the small number of included studies.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"Race and ethnicity data were inconsistently reported across trials, preventing subgroup analyses by demographic factors.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"The Judson 2014 trial included both golimumab and ustekinumab arms with a shared placebo group; the authors split the placebo arm proportionally to avoid unit-of-analysis errors, which introduces analytical uncertainty.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"The level of evidence tag '1' reflects the meta-analysis of RCTs study design, but GRADE certainty was rated 'very low' due to risk of bias, imprecision, and heterogeneity — the clinical confidence in the pooled estimates is therefore much lower than the design hierarchy alone implies.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis of 6 double-blind, placebo-controlled RCTs (n=156 adults) evaluated the efficacy and safety of pharmacological add-on therapies — including infliximab, adalimumab, golimumab, ustekinumab, thalidomide, sirolimus (topical mTOR inhibitor), and the CLEAR antimycobacterial regimen — for cutaneous sarcoidosis, with all trials permitting concomitant corticosteroids.","key_result":"No pharmacological therapy significantly improved clinical response over placebo (OR 2.24; 95% CI 0.73–6.90; p=0.16). A non-significant trend toward better quality of life was seen (OR 2.23; 95% CI 0.87–5.73; p=0.09). Serious adverse events were similar between groups (OR 0.97; 95% CI 0.48–1.96; p=0.93). Overall certainty of evidence was very low (GRADE).","limitations":"- Only 6 RCTs with 156 total participants; severely underpowered for definitive conclusions.\n- Risk of bias was moderate-to-high in 4 of 6 studies, mainly due to missing outcome data and inadequate allocation concealment.\n- All trials allowed concurrent corticosteroids without standardized dosing or tapering, which may have blunted detection of treatment benefit. Publication bias could not be assessed.","practice_takeaway":"Current RCT evidence does not support a statistically significant benefit of steroid-sparing add-on therapies for cutaneous sarcoidosis; individualize treatment based on disease severity, comorbidities, and patient preferences. Emerging agents (JAK inhibitors, mTOR inhibitors) show promise in case reports but lack controlled trial data — do not use as standard care yet."}},{"doi":"10.1007/s10620-026-10231-1","pmid":"42704580","title":"IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review","journal_title":"Digestive Diseases and Sciences","journal_issn":"0163-2116","published_at":"2026-09-07T00:00:00.000Z","url":"https://doi.org/10.1007/s10620-026-10231-1","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-15T06:17:42.129Z","updated_at":"2026-09-15T06:17:42.129Z","tags":[{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"etrasimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"filgotinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"obefazimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"ozanimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"Anti-Integrin","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"Anti-TNF Agent","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"S1P Receptor Modulator","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"Evidence maturity varies considerably across domains: infection screening and infusion safety are well-supported, while remote monitoring and small-molecule nursing roles rest on a more heterogeneous evidence base.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"No sample size applies — this is a narrative review synthesizing existing literature, not a primary study with enrolled participants.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"Sex of study populations is not reported, as this review aggregates evidence across multiple heterogeneous sources.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"The seven nursing domains represent an interpretative synthesis, not a validated clinical framework; they have not undergone formal consensus, feasibility testing, or outcome evaluation.","value_numeric":null}],"summaries":{"what_studied":"This narrative review synthesized clinical, organizational, and nursing evidence on the role of specialist IBD nurses in managing biologic and small-molecule therapies, drawing on ECCO, BSG, and ACG guidelines plus literature up to December 2025 (with an August 2026 update).","key_result":"Seven interrelated nursing practice domains were identified: pretreatment assessment, therapy preparation, IV infusion management, self-administered therapy management, clinical and laboratory monitoring, critical event management, and core knowledge of biologic/small-molecule therapies. An eighth complementary section covers emerging therapies and special contexts (pregnancy, perianal disease, travel, pediatric/adolescent transition).","limitations":"- Narrative design lacks the exhaustiveness, reproducibility, and formal evidence appraisal of a systematic review; relevant sources may have been missed.\n- Included literature is highly heterogeneous (guidelines, observational studies, service reports, digital-health evaluations), limiting comparative conclusions about individual pathway components.\n- No formal framework-development process was conducted (no expert consensus, stakeholder validation, feasibility testing, or implementation evaluation), so the thematic domains should not be treated as a validated clinical framework or standard of care.","practice_takeaway":"IBD nurses should follow structured, protocol-driven pathways across all phases of advanced therapy—from infectious screening and pharmacogenetic testing before initiation, to predefined escalation algorithms for infusion reactions, infections, VTE, and cardiovascular events. Centers developing or expanding IBD nursing services can use the seven domains as an evidence-informed starting point, while recognizing that formal validation and local adaptation are still needed."}},{"doi":"10.1001/jamadermatol.2026.1457","pmid":"42268620","title":"Golimumab in Treatment-Refractory Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-06-10T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1457","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-14T13:34:42.490Z","updated_at":"2026-06-14T13:34:42.490Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"brand","value":"Simponi","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Golimumab is not currently FDA-approved for hidradenitis suppurativa; this represents an off-label use investigation.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Level of evidence set to 3 based on cohort study design; may need revision upon full-text review.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Only the abstract was provided; key results, sample size, follow-up duration, and comparator arms are not available — most summary fields and tags cannot be fully populated.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1457","tag_type":"warning","value":"Sex of study population is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This cohort study evaluated the association between changes in IHS4 (International Hidradenitis Suppurativa Severity Score System) scores and treatment with intravenous or subcutaneous golimumab in patients with moderate to severe, treatment-refractory hidradenitis suppurativa.","limitations":"Abstract-only data available; specific outcomes, sample size, follow-up duration, and comparator details are not reported.","practice_takeaway":"Golimumab (IV and SC) is being explored as an option for treatment-refractory moderate-to-severe HS; clinicians should await full study data before adopting this into routine practice."}},{"doi":"10.1002/art.70152","pmid":"41878957","title":"Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study","journal_title":"Arthritis & Rheumatology","journal_issn":"2326-5191","published_at":"2026-05-11T00:00:00.000Z","url":"https://doi.org/10.1002/art.70152","source_score":4,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-19T13:22:45.777Z","updated_at":"2026-05-19T13:22:45.777Z","tags":[{"paper_doi":"10.1002/art.70152","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"brand","value":"Simponi","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"sample_size","value":"n=91","value_numeric":91},{"paper_doi":"10.1002/art.70152","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"warning","value":"ACR50 and MDA p-values in the CRP subgroup are nominal (not adjusted for multiplicity), increasing the risk of false-positive findings.","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"warning","value":"A protocol deviation allowed enrollment of patients regardless of CRP level, creating a mixed population that diluted the intended treatment effect.","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"warning","value":"Brand name 'Tremfya' noted for guselkumab; the paper does not specify which brand name was used in the trial context.","value_numeric":null},{"paper_doi":"10.1002/art.70152","tag_type":"warning","value":"Primary endpoint was not met in the overall population; positive signals in the CRP ≥0.3 mg/dL subgroup are from an exploratory/post-hoc analysis and should be interpreted cautiously.","value_numeric":null}],"summaries":{"what_studied":"This phase 2a RCT evaluated subcutaneous guselkumab (100 mg) + golimumab (50 mg) combination therapy vs. guselkumab monotherapy (both every 4 weeks through week 20) in adults with active TNFi-inadequate response PsA (≥3 tender/swollen joints), with a primary endpoint of week 24 minimal disease activity (MDA).","key_result":"The primary endpoint was not met: MDA at week 24 was 29% (combo) vs. 22% (mono), OR 1.4 [90% CI 0.6–3.3], P=0.557. However, in the intended subgroup with CRP ≥0.3 mg/dL (n=40 combo, n=22 mono), combination therapy showed markedly better MDA (32% vs. 5%, OR 12.3, nominal P=0.025) and ACR50 (55% vs. 14%, OR 9.6, nominal P=0.003). No new safety signals, tuberculosis, or opportunistic infections occurred through week 36.","limitations":"- Primary endpoint missed in the overall population, partly due to a protocol deviation that enrolled patients regardless of CRP level (diluting the intended high-inflammation cohort).\n- Small sample size (n=91 total) and 2:1 randomization limit statistical power.\n- Phase 2a proof-of-concept design; results are hypothesis-generating and not confirmatory.","practice_takeaway":"For TNFi-inadequate responders with active PsA and elevated CRP (≥0.3 mg/dL), the guselkumab + golimumab dual-biologic combination showed clinically meaningful ACR50 and MDA signals worth monitoring in future trials. This combination should not yet be adopted in routine practice, but clinicians may watch for phase 3 data in this CRP-elevated subgroup."}},{"doi":"10.1136/rmdopen-2025-006593","pmid":"42049394","title":"Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort","journal_title":"RMD Open","journal_issn":"2056-5933","published_at":"2026-04-29T00:00:00.000Z","url":"https://doi.org/10.1136/rmdopen-2025-006593","source_score":17,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-30","doi":"10.1136/rmdopen-2025-006593","days":"14","issn":"2056-5933","rank":"6","field":"Clinical Medicine","score":"17","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1136/rmdopen-2025-006593","title":"Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort.","journal":"RMD open","methods":"This ancillary study from the French multicentre prospective cohort (GR2-NCT02450396) included pregnant women with RA and SpA with at least one postpartum visit from October 2014 to October 2022. Disease activity, flares, treatments and breastfeeding rates were described. Factors associated with the occurrence of a flare were evaluated by survival analysis. Disease activity was compared according to breastfeeding duration (never, <6 months and ≥6 months).","results":"Ninety-four RA and 124 SpA patients were studied. In RA patients, the proportion of patients presenting with at least one flare was significantly higher during the first 6 months postpartum compared with pregnancy (62.0% vs 43.5%; p=0.02). For SpA patients, there was no difference in disease activity at 6 months postpartum compared with pregnancy (40.7% vs 40.7%; p=0.999). Disease activity in postpartum was similar between the different breastfeeding status in both diseases. 13/91 (14.3%) RA patients and 29/123 (23.6%) SpA patients continued a biologic Disease-Modifying Antirheumatic Drug (bDMARD) during the whole pregnancy and the postpartum. 78/91 RA and 94/123 SpA patients delivered without any DMARDs, and among them, 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum.","abstract":"$30","keywords":["Arthritis, Rheumatoid","Axial Spondyloarthritis","Biological Therapy"],"pubmed_id":"42049394","conclusions":"RA patients were more likely to flare during early postpartum, while SpA patients remained stable. bDMARD continuation during pregnancy was more frequent in SpA patients, and half of the patients restarted bDMARD during postpartum.","publication_date":"2026-04-29T00:00:00"},"crossref":{"DOI":"10.1136/rmdopen-2025-006593","URL":"https://doi.org/10.1136/rmdopen-2025-006593","ISSN":["2056-5933"],"link":[{"URL":"https://syndication.highwire.org/content/doi/10.1136/rmdopen-2025-006593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"e006593","type":"journal-article","issue":"2","score":1,"title":["Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort"],"author":[{"given":"Marie","family":"Hornez","sequence":"first","affiliation":[{"name":"Service de Rhumatologie, Université de Lille, CHU Lille, Lille, France"}]},{"given":"Anna","family":"Molto","sequence":"additional","affiliation":[{"name":"Centre for Research in Epidemiology and Statistics, Université Paris Cité; Université Sorbonne Paris Nord; INSERM; INRAE, Paris, France"},{"name":"Service de Rhumatologie, Hôpital Bichat, APHP, Paris, France"}]},{"given":"Maxime","family":"Leroy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, CHU Lille, Lille, France"}]},{"given":"Béatrice","family":"Banneville","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France"}]},{"given":"Rakiba","family":"Belkhir","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicetre, France"}]},{"given":"Elodie","family":"Chauvet","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, CHU Montpellier, Montpellier, France"}]},{"given":"Marion","family":"Couderc","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand, France"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Caen, Caen, France"}]},{"given":"Valérie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne occidentale, Inserm, CHU Brest, LabEx IGO, Brest, France"},{"name":"Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINOM), CHU, Brest, France"}]},{"given":"Aline","family":"Frazier","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Paris Cité, AP-HP, Hôpital Lariboisière, Paris, France"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France"}]},{"given":"Elisabeth","family":"Gervais","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Poitiers, Poitiers, France"}]},{"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Jean Monnet Saint-Étienne, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Étienne, France"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, National Reference Center for Systemic Autoimmune Rare Diseases, Bordeaux University Hospital, Hôpital Pellegrin, Bordeaux, France"},{"name":"CNRS, Immunoconcept, UMR 5164, Bordeaux University, Bordeaux, France"}]},{"given":"Jérémie","family":"Sellam","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Hôpital Saint-Antoine; Assistance Publique–Hôpitaux de Paris (AP-HP); Sorbonne Université, Paris, France"}]},{"given":"Raphaele","family":"Seror","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicetre, France"}]},{"given":"Véronique","family":"Le Guern","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP Hôpital Cochin, Paris, France"}]},{"given":"Gaëlle","family":"Guettrot-Imbert","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP Hôpital Cochin, Paris, France"}]},{"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP Hôpital Cochin, Paris, France"}]},{"given":"René-Marc","family":"Flipo","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université de Lille, CHU Lille, FHU PRECISE, Lille, France"}]},{"given":"Jean-Guillaume","family":"Letarouilly","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, Université de Lille, CHU Lille, FHU PRECISE, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France"}]}],"funder":[{"name":"the Association Prix Veronique Roualet"},{"id":[{"id":"10.13039/100011110","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100011110","name":"UCB","doi-asserted-by":"publisher"},{"name":"AFM-Telethon"},{"name":"Cochin Hospital"},{"name":"Association Francophone contre la Polychondrite chronique atrophiante"},{"id":[{"id":"10.13039/100020799","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100020799","name":"Association des Sclérodermiques de France","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100014034","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher"},{"name":"the French Society of Internal Medicine and Rheumatology"},{"name":"Association Gougerot Sjogren"},{"name":"The French Health Ministry"},{"name":"Lupus France"}],"issued":{"date-parts":[[2026,4]]},"member":"239","prefix":"10.1136","source":"Crossref","volume":"12","created":{"date-time":"2026-04-28T13:25:21Z","timestamp":1777382721000,"date-parts":[[2026,4,28]]},"indexed":{"date-time":"2026-04-29T12:21:56Z","timestamp":1777465316482,"date-parts":[[2026,4,29]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000,"date-parts":[[2026,4,28]]},"delay-in-days":27,"content-version":"unspecified"}],"subject":[],"abstract":"$31","accepted":{"date-parts":[[2026,3,31]]},"language":"en","relation":{},"resource":{"primary":{"URL":"https://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2025-006593"}},"subtitle":[],"deposited":{"date-time":"2026-04-28T13:25:26Z","timestamp":1777382726000,"date-parts":[[2026,4,28]]},"issn-type":[{"type":"electronic","value":"2056-5933"}],"published":{"date-parts":[[2026,4]]},"publisher":"BMJ","reference":[{"DOI":"10.1016/j.jbspin.2021.105289","key":"2026042806251264000_12.2.e006593.1","year":"2022","issue":null,"author":"Fakih","volume":"89","first-page":"105289","unstructured":null,"article-title":"Differences in distribution by department of prevalence and incidence of spondyloarthritis and inflammatory bowel diseases declared to the French National Health Insurance and their evolution between 2008 and 2018","journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbspin.2022.105460","key":"2026042806251264000_12.2.e006593.2","year":"2023","issue":null,"author":"Pina Vegas","volume":"90","first-page":"105460","unstructured":null,"article-title":"Prevalence, mortality, and treatment of patients with rheumatoid arthritis: A cohort study of the French National Health Data System, 2010-2019","journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hench PS . The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis, and intermittent hydrarthrosis. In: Classic Papers in Rheumatology. CRC Press, 2001.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1002/1529-0131(199906)42:6<1219::AID-ANR19>3.0.CO;2-G","key":"2026042806251264000_12.2.e006593.4","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.24003","key":"2026042806251264000_12.2.e006593.5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.180226","key":"2026042806251264000_12.2.e006593.6","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-021-05588-9","key":"2026042806251264000_12.2.e006593.7","year":"2021","issue":null,"author":"Mokbel","volume":"40","first-page":"3465","unstructured":null,"article-title":"Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review","journal-title":"Clin Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/ard.2003.016881","key":"2026042806251264000_12.2.e006593.8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/key047","key":"2026042806251264000_12.2.e006593.9","year":"2018","issue":null,"author":"Ursin","volume":"57","first-page":"1064","unstructured":null,"article-title":"Disease activity during and after pregnancy in women with axial spondyloarthritis: a prospective multicentre study","journal-title":"Rheumatology (Sunnyvale)","doi-asserted-by":"crossref"},{"DOI":"10.3899/jrheum.180805","key":"2026042806251264000_12.2.e006593.10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3899/jrheum.181067","key":"2026042806251264000_12.2.e006593.11","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.1780370605","key":"2026042806251264000_12.2.e006593.12","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/1529-0131(200005)43:5<1010::AID-ANR8>3.0.CO;2-O","key":"2026042806251264000_12.2.e006593.13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/ard.2007.084707","key":"2026042806251264000_12.2.e006593.14","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.20621","key":"2026042806251264000_12.2.e006593.15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-018-04415-y","key":"2026042806251264000_12.2.e006593.16","year":"2019","issue":null,"author":"Vieira Borba","volume":"38","first-page":"1263","unstructured":null,"article-title":"Prolactin, autoimmunity, and motherhood: when should women avoid breastfeeding?","journal-title":"Clin Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/rheumatology/kev404","key":"2026042806251264000_12.2.e006593.17","year":"2016","issue":null,"author":"Flint","volume":"55","first-page":"1693","unstructured":null,"article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1","journal-title":"Rheumatology (Sunnyvale)","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2015-208840","key":"2026042806251264000_12.2.e006593.18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.41191","key":"2026042806251264000_12.2.e006593.19","year":"2020","issue":null,"author":"Sammaritano","volume":"72","first-page":"529","unstructured":null,"article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","journal-title":"Arthritis Rheumatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"European Network of Pregnancy Registers in Rheumatology (EuNeP) . An overview of procedures and data collection. Arthritis Research & Therapy. Available: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2019-3 [Accessed 03 May 2023].","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/s13075-019-2019-3","key":"2026042806251264000_12.2.e006593.21","year":"2019","issue":null,"author":"Meissner","volume":"21","first-page":null,"unstructured":null,"article-title":"European Network of Pregnancy Registers in Rheumatology (EuNeP)-an overview of procedures and data collection","journal-title":"Arthritis Res Ther","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2020-218356","key":"2026042806251264000_12.2.e006593.22","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(23)00099-1","key":"2026042806251264000_12.2.e006593.23","year":"2023","issue":null,"author":"de Frémont","volume":"5","first-page":"e330","unstructured":null,"article-title":"Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study","journal-title":"Lancet Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2665-9913(22)00308-3","key":"2026042806251264000_12.2.e006593.24","year":"2022","issue":null,"author":"Murarasu","volume":"4","first-page":"e842","unstructured":null,"article-title":"Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study","journal-title":"Lancet Rheumatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.25","year":"2014","issue":null,"author":"van Riel","volume":"32","first-page":"65","unstructured":null,"article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)","journal-title":"Clin Exp Rheumatol","doi-asserted-by":null},{"DOI":"10.1016/j.jbspin.2022.105505","key":"2026042806251264000_12.2.e006593.26","year":"2023","issue":null,"author":"Valero","volume":"90","first-page":"105505","unstructured":null,"article-title":"Evaluating remission and low disease activity from the perspective of the patient with axial spondyloarthritis: The cross-sectional ConREspAx study","journal-title":"Joint Bone Spine","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijmr.IJMR_701_15","key":"2026042806251264000_12.2.e006593.27","year":"2017","issue":null,"author":"Kumar","volume":"146","first-page":"S57","unstructured":null,"article-title":"Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation","journal-title":"Indian J Med Res","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.28","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Partial residuals for the proportional hazards regression model. ResearchGate; 2025. Available: https://www.researchgate.net/publication/30941900_Partial_Residuals_for_The_Proportional_Hazards_Regression_Model [Accessed 16 Sep 2025].","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1136/annrheumdis-2021-eular.420","key":"2026042806251264000_12.2.e006593.29","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2021.722118","key":"2026042806251264000_12.2.e006593.30","year":"2021","issue":null,"author":"Wirestam","volume":"12","first-page":null,"unstructured":null,"article-title":"Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy","journal-title":"Front Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1136/ard-2022-222641","key":"2026042806251264000_12.2.e006593.31","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2018.08.008","key":"2026042806251264000_12.2.e006593.32","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/rmdopen-2022-002194","key":"2026042806251264000_12.2.e006593.33","year":"2022","issue":null,"author":"Kemper","volume":"8","first-page":null,"unstructured":null,"article-title":"Active counselling and well-controlled disease result in a higher percentage of women with rheumatoid arthritis that breast feed: results from the PreCARA study","journal-title":"RMD Open","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00404-022-06463-x","key":"2026042806251264000_12.2.e006593.34","year":"2022","issue":null,"author":"Allen","volume":"306","first-page":"1929","unstructured":null,"article-title":"Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare","journal-title":"Arch Gynecol Obstet","doi-asserted-by":"crossref"},{"DOI":"10.3389/fphar.2022.887462","key":"2026042806251264000_12.2.e006593.35","year":"2022","issue":null,"author":"Gerardi","volume":"13","first-page":null,"unstructured":null,"article-title":"Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis","journal-title":"Front Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13075-017-1269-1","key":"2026042806251264000_12.2.e006593.36","year":"2017","issue":null,"author":"van den Brandt","volume":"19","first-page":null,"unstructured":null,"article-title":"Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients","journal-title":"Arthritis Res Ther","doi-asserted-by":"crossref"},{"DOI":"10.3899/jrheum.171152","key":"2026042806251264000_12.2.e006593.37","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(15)01024-7","key":"2026042806251264000_12.2.e006593.38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"2026042806251264000_12.2.e006593.39","year":"2021","issue":null,"author":"Coulm","volume":"20","first-page":"10","unstructured":null,"article-title":"Allaiter en France aujourd’hui","journal-title":"Sages-Femmes","doi-asserted-by":null},{"DOI":"10.1016/j.jgyn.2015.09.026","key":"2026042806251264000_12.2.e006593.40","year":"2015","issue":null,"author":"Chantry","volume":"44","first-page":"1071","unstructured":null,"article-title":"Breastfeeding (part one): Frequency, benefits and drawbacks, optimal duration and factors influencing its initiation and prolongation. Clinical guidelines for practice","journal-title":"J Gynecol Obstet Biol Reprod (Paris)","doi-asserted-by":"crossref"},{"DOI":"10.1136/lupus-2021-000491","key":"2026042806251264000_12.2.e006593.41","year":"2021","issue":null,"author":"Ikram","volume":"8","first-page":null,"unstructured":null,"article-title":"Breastfeeding in women with rheumatic diseases","journal-title":"Lupus Sci Med","doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2017.00720","key":"2026042806251264000_12.2.e006593.42","year":"2017","issue":null,"author":"Tang","volume":"8","first-page":null,"unstructured":null,"article-title":"Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis","journal-title":"Front Immunol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]},"published-online":{"date-parts":[[2026,4,28]]}},"update-policy":"https://doi.org/10.1136/crossmarkpolicy","alternative-id":["10.1136/rmdopen-2025-006593"],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"original-title":[],"container-title":["RMD Open"],"published-print":{"date-parts":[[2026,4]]},"reference-count":42,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,28]]},"references-count":42,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct02450396"},{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct02450396"}],"short-container-title":["RMD Open"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1136/rmdopen-2025-006593","is_oa":true,"title":"Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort","updated":"2026-05-09T14:24:07+00:00","published_date":"2026-04-01","best_oa_location":{"url":"https://doi.org/10.1136/rmdopen-2025-006593","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1136/rmdopen-2025-006593"}}},"created_at":"2026-05-14T13:22:56.018Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"condition","value":"Rheumatoid Arthritis","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"condition","value":"Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"certolizumab pegol","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"generic","value":"sulfasalazine","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"modality","value":"Biologic Disease-Modifying Antirheumatic Drug","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"modality","value":"Biologic DMARD","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"modality","value":"TNF Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"sample_size","value":"n=218","value_numeric":218},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"study_design","value":"Prospective Cohort","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Certolizumab pegol is classified here under TNF alpha inhibitors and listed by generic name; no brand-level data were reported in the paper.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Definitions of flare and the specific disease activity measures are not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Disease activity scores were frequently missing, especially CRP, which may have reduced sensitivity to detect objective changes in activity.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Observational ancillary cohort analysis without randomized comparisons; causal inferences are limited.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Self-reported flare definitions may overestimate true flare rates compared to validated score-based definitions.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"The association between bDMARD resumption and postpartum flare is likely reverse causation (flare prompts treatment restart) rather than treatment causing flare—authors acknowledge this.","value_numeric":null},{"paper_doi":"10.1136/rmdopen-2025-006593","tag_type":"warning","value":"Treatment denominators (e.g., 91/123) differ from total enrolled (94/124), suggesting missing data or exclusions.","value_numeric":null}],"summaries":{"what_studied":"An ancillary analysis of a French multicentre prospective cohort (GR2) followed pregnant women with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who had at least one postpartum visit (2014–2022) to describe disease activity, flares, breastfeeding, and treatments. Postpartum disease activity was compared with pregnancy, flares were examined with survival analysis, and outcomes were explored by breastfeeding duration (never, <6 months, ≥6 months).","key_result":"In RA, the proportion with at least one flare in the first 6 months postpartum was higher than during pregnancy (62.0% vs 43.5%; p=0.02). In SpA, disease activity at 6 months postpartum was unchanged versus pregnancy (40.7% vs 40.7%; p=0.999); postpartum activity did not differ by breastfeeding status in either disease; 13/91 (14.3%) RA and 29/123 (23.6%) SpA continued a bDMARD through pregnancy and postpartum, and among those delivering without any DMARDs (RA 78/91; SpA 94/123), 43/78 (55.1%) and 56/94 (59.6%) (re)started a bDMARD postpartum.","limitations":"Only patients with at least one postpartum visit were included, and denominators varied across analyses (e.g., 91/123 vs totals 94/124), indicating missing data or exclusions. The abstract does not specify flare definitions or disease activity measures, and adjusted analyses are not reported.","practice_takeaway":"Plan closer monitoring of women with RA in the first 6 months after delivery, when flares were more frequent than during pregnancy; SpA activity appeared stable. Breastfeeding did not change postpartum activity, and many who stopped DMARDs in pregnancy restarted bDMARDs after delivery."}},{"doi":"10.1002/art.70132","pmid":"41841636","title":"Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans","journal_title":"Arthritis & Rheumatology","journal_issn":"2326-5191","published_at":"2026-03-17T00:00:00.000Z","url":"https://doi.org/10.1002/art.70132","source_score":24,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-25","doi":"10.1002/art.70132","days":"30","issn":"2326-5191","rank":"7","field":"Clinical Medicine","score":"24","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1002/art.70132","title":"Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand-Alone Part D Plans.","journal":"Arthritis & rheumatology (Hoboken, N.J.)","methods":"","results":"We included 26,915 plan-year observations, representing 217.6 million enrolled beneficiaries from 2022 to 2026. In the five-year period, coverage was relatively complete (>94%) for etanercept and adalimumab (TNF inhibitors) and upadacitinib (JAK inhibitor). However, coverage was lower for golimumab and certolizumab (TNF inhibitors), abatacept (the sole T cell costimulatory modulator), sarilumab (IL-6 inhibitor), and baricitinib (JAK inhibitor). Moreover, only 10.4% and 37.6% of stand-alone and Medicare Advantage (MA) Part D plans, respectively, covered all mechanisms of action, mostly due to low coverage of abatacept. In 2026, only 0.3% and 21.2% of stand-alone and MA Part D plans, respectively, covered abatacept. On the other hand, coverage increased for IL-6 inhibitors, likely due to the availability of biosimilar drugs for tocilizumab in 2024.","abstract":"$32","keywords":[],"pubmed_id":"41841636","conclusions":"The growing exclusions of self-administered DMARDs across several mechanisms of action and heterogeneity in coverage by plan type suggest potential barriers to accessing optimal RA treatments. Further monitoring of formulary adequacy and research into the clinical impacts of formulary exclusions are warranted.","publication_date":"2026-03-17T00:00:00"},"crossref":{"DOI":"10.1002/art.70132","URL":"https://doi.org/10.1002/art.70132","ISSN":["2326-5191","2326-5205"],"link":[{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.70132","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/full-xml/10.1002/art.70132","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.70132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans"],"author":[{"given":"Youngmin","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Health Policy Vanderbilt University Medical Center Nashville Tennessee"}]},{"given":"Robert W.","family":"Corty","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy Vanderbilt University Medical Center Nashville Tennessee"}]}],"funder":[{"id":[{"id":"10.13039/100014848","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,4,20]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2026-03-17T12:20:22Z","timestamp":1773750022000,"date-parts":[[2026,3,17]]},"indexed":{"date-time":"2026-04-20T08:28:17Z","timestamp":1776673697303,"date-parts":[[2026,4,20]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000,"date-parts":[[2026,4,20]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000,"date-parts":[[2026,4,20]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70132"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-10-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-02-26"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-04-20"}],"deposited":{"date-time":"2026-04-20T07:28:00Z","timestamp":1776670080000,"date-parts":[[2026,4,20]]},"issn-type":[{"type":"print","value":"2326-5191"},{"type":"electronic","value":"2326-5205"}],"published":{"date-parts":[[2026,4,20]]},"publisher":"Wiley","reference":[{"DOI":"10.18553/jmcp.2019.25.8.879","key":"e_1_2_6_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/acr.24596","key":"e_1_2_6_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/nrrheum.2010.45","key":"e_1_2_6_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.24560","key":"e_1_2_6_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.39079","key":"e_1_2_6_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_7_1","year":"2024","issue":null,"author":"Howlett J","volume":null,"first-page":null,"unstructured":null,"article-title":"Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs","journal-title":"STAT","doi-asserted-by":null},{"DOI":"10.1093/rap/rky005","key":"e_1_2_6_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_9_1","year":"2024","issue":null,"author":"Cubanski J.","volume":null,"first-page":null,"unstructured":null,"article-title":"A current snapshot of the Medicare Part D prescription drug benefit","journal-title":"KFF","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_10_1","year":"2019","issue":null,"author":"Duddy‐Tenbrunsel R","volume":null,"first-page":null,"unstructured":null,"article-title":"Over half of Medicare Advantage beneficiaries enrolled in plans that require step therapy for new starts of Part B RA biologics in 2019","journal-title":"Avalere Health","doi-asserted-by":null},{"DOI":"10.2147/CEOR.S317687","key":"e_1_2_6_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18553/jmcp.2023.29.6.607","key":"e_1_2_6_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1377/hlthaff.2024.01527","key":"e_1_2_6_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Centers for Medicare and Medicaid Services.Quarterly prescription drug plan formulary pharmacy network and pricing information. May 22 2025. Accessed June 11 2025.https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers/quarterly-prescription-drug-plan-formulary-pharmacy-network-and-pricing-information","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Centers for Medicare and Medicaid Services.Formulary guidance. August 8 2025. Accessed August 21 2025.https://www.cms.gov/medicare/coverage/prescription-drug-coverage/formulary-guidance","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1136/amiajnl-2011-000116","key":"e_1_2_6_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7326/0003-4819-145-6-200609190-00008","key":"e_1_2_6_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Centers for Medicare and Medicaid Services.Medicare Advantage/Part D contract and enrollment data. February 27 2025. Accessed August 21 2025.https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-advantagepart-d-contract-and-enrollment-data","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/jama.2025.7289","key":"e_1_2_6_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1358/dot.2009.45.6.1378935","key":"e_1_2_6_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.rdc.2004.01.005","key":"e_1_2_6_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(23)00268-0","key":"e_1_2_6_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18553/jmcp.2017.23.8.809","key":"e_1_2_6_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2019.102398","key":"e_1_2_6_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1377/forefront.20231117.71714","key":"e_1_2_6_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Organization for Rare Disorders.Changes to Medicare for 2025 and beyond: important information for the rare disease community ahead of open enrollment. September 16 2024. Accessed June 30 2025.https://rarediseases.org/medicare-ira-changes/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"NguyenA LiD.Being in the wrong Medicare Part D plan could cost over $800 per year. December 1 2022. Accessed July 1 2025.https://www.goodrx.com/healthcare-access/research/medicare-part-d-unrealized-savings","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_28_1","year":"2024","issue":null,"author":"Ochieng N","volume":null,"first-page":null,"unstructured":null,"article-title":"Nearly 7 in 10 Medicare beneficiaries did not compare plans during Medicare's open enrollment period","journal-title":"KFF","doi-asserted-by":null},{"DOI":"10.1093/haschl/qxae141","key":"e_1_2_6_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"MarshT LiD.The big pinch: fewer medications covered more restrictions on covered drugs. June 26 2024. Accessed July 1 2025.https://www.goodrx.com/insurance/health-insurance/the-big-pinch-fewer-prescription-drugs-covered-more-insurance-restrictions","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/jamainternmed.2018.6417","key":"e_1_2_6_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"American Journal of Managed Care.Cost considerations for self‐ vs HCP‐administered agents. October 12 2020. Accessed January 16 2026.https://www.ajmc.com/view/cost-considerations-for-self-vs-hcp-administered-agents","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s40259-018-0295-0","key":"e_1_2_6_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1468-0009.12565","key":"e_1_2_6_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Centers for Medicare and Medicaid Services.Medicare prescription drug benefit manual. January 15 2016. Accessed June 28 2025.https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/downloads/part-d-benefits-manual-chapter-6.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"HuskampHA KeatingNL.The new Medicare drug benefit: potential effects of pharmacy management tools on access to medications. July2004. Accessed June 28 2025.https://www.kff.org/wp-content/uploads/2013/01/the-new-medicare-drug-benefit-potential-effects-of-pharmacy-management-tools-on-access-to-medications.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1377/hlthaff.2024.00273","key":"e_1_2_6_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_6_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Medicare Access for Patient Rx.Hope for the best prepare for the worst: the Inflation Reduction Act's unintended consequences for Medicare Part D in 2025 and 2026. August 23 2024. Accessed November 23 2024.https://maprx.info/wp-content/uploads/2024/08/MAPRx_whitepaper_2024-08-15_Final.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"EVERSANA.Special Report: Inflation Reduction Act sets Part D stakeholders scrambling. September 28 2022. Accessed June 28 2025.https://www.eversana.com/2022/09/28/special-report-inflation-reduction-act-sets-part-d-stakeholders-scrambling/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_6_40_1","year":"2019","issue":null,"author":"Lampner C.","volume":null,"first-page":null,"unstructured":null,"article-title":"Switch or swap: strategies for anti‐TNF failure in rheumatoid arthritis","journal-title":"Rheumatology Advisor.","doi-asserted-by":null}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/art.70132"],"article-number":"art.70132","content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Arthritis & Rheumatology"],"reference-count":39,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,20]]},"references-count":39,"short-container-title":["Arthritis & Rheumatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/art.70132","is_oa":true,"title":"Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans","updated":"2026-04-21T12:05:45+00:00","published_date":"2026-03-17","best_oa_location":{"url":"https://doi.org/10.1002/art.70132","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1002/art.70132"}}},"created_at":"2026-05-07T22:49:27.383Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1002/art.70132","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Actemra","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Cimzia","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Kevzara","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Olumiant","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Orencia","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"brand","value":"Simponi","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"condition","value":"Rheumatoid Arthritis","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"abatacept","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"baricitinib","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"certolizumab","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"sarilumab","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"tocilizumab","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"modality","value":"Biosimilar","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"modality","value":"IL-6 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"modality","value":"T Cell Costimulatory Modulator","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"sample_size","value":"n=26,915 plan-year observations","value_numeric":26915},{"paper_doi":"10.1002/art.70132","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"warning","value":"Sample size reflects plan-year observations (n=26,915), not individual patients; the 217.6 million figure represents cumulative enrolled beneficiaries across plan-years and should not be interpreted as unique patients.","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"warning","value":"Study design is best characterized as a repeated cross-sectional analysis of administrative formulary data; no causal inference about patient outcomes is possible.","value_numeric":null},{"paper_doi":"10.1002/art.70132","tag_type":"warning","value":"The 'safety_signal' impact flag is applied here in the access/policy sense — formulary exclusions represent a barrier to care signal, not a drug safety signal in the traditional adverse-event sense.","value_numeric":null}],"summaries":{"what_studied":"Coverage generosity of self-administered DMARDs (TNF inhibitors, T cell costimulatory modulator, IL-6 inhibitors, JAK inhibitors) across Medicare Part D stand-alone and Medicare Advantage plans from 2022–2026, using 26,915 plan-year observations representing 217.6 million enrolled beneficiaries.","key_result":"Coverage exceeded 94% for etanercept, adalimumab, and upadacitinib, but was markedly lower for abatacept (only 0.3% of stand-alone and 21.2% of MA Part D plans covered it in 2026). Only 10.4% of stand-alone and 37.6% of MA plans covered all mechanisms of action. IL-6 inhibitor coverage improved after tocilizumab biosimilars launched in 2024.","limitations":"Formulary data reflect plan-level coverage but do not capture actual patient-level access, utilization, or clinical outcomes resulting from exclusions. The study period ends at 2026, so long-term trends cannot be assessed. Reasons behind specific formulary exclusion decisions (e.g., rebate negotiations) are not examined.","practice_takeaway":"Clinicians prescribing abatacept or less-covered DMARDs to Medicare patients should proactively verify formulary status, as coverage varies widely by plan type and has been declining. Awareness of biosimilar-driven coverage gains (e.g., tocilizumab biosimilars) may help identify accessible alternatives when preferred agents are excluded."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"golimumab"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"golimumab"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"golimumab"}}}]]